Amplia Therapeutics Ltd. (AU:ATX)
ASX:ATX
Want to see AU:ATX full AI Analyst Report?
Total Valuation
Amplia Therapeutics has a market cap or net worth of AU$56.46M. The enterprise value is AU$41.75M.
Market CapAU$56.46M
Enterprise ValueAU$41.75M
Share Statistics
Amplia Therapeutics has 513,312,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding513,312,000
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Amplia Therapeutics’s return on equity (ROE) is -0.20 and return on invested capital (ROIC) is -20.41%.
Return on Equity (ROE)-0.20
Return on Assets (ROA)-0.19
Return on Invested Capital (ROIC)-20.41%
Return on Capital Employed (ROCE)-0.33
Revenue Per Employee0.00
Profits Per Employee-7.71M
Employee Count1
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Amplia Therapeutics is ―. Amplia Therapeutics’s PEG ratio is 0.61.
PE Ratio―
PS Ratio0.00
PB Ratio2.80
Price to Fair Value2.80
Price to FCF-12.59
Price to Operating Cash Flow-6.46
PEG Ratio0.61
Income Statement
In the last 12 months, Amplia Therapeutics had revenue of 0.00 and earned -7.71M in profits. Earnings per share was -0.02.
Revenue0.00
Gross Profit-92.14K
Operating Income-13.18M
Pretax Income-12.49M
Net Income-7.71M
EBITDA-13.09M
Earnings Per Share (EPS)-0.02
Cash Flow
In the last 12 months, operating cash flow was -8.73M and capital expenditures -33.31K, giving a free cash flow of -8.77M billion.
Operating Cash Flow-8.73M
Free Cash Flow-8.77M
Free Cash Flow per Share-0.02
Dividends & Yields
Amplia Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.19
52-Week Price Change66.67%
50-Day Moving Average0.15
200-Day Moving Average0.14
Relative Strength Index (RSI)37.06
Average Volume (3m)525.22K
Important Dates
Amplia Therapeutics upcoming earnings date is Nov 25, 2026, TBA (Confirmed).
Last Earnings DateMay 29, 2026
Next Earnings DateNov 25, 2026
Ex-Dividend Date―
Financial Position
Amplia Therapeutics as a current ratio of 19.78, with Debt / Equity ratio of 0.86%
Current Ratio19.78
Quick Ratio19.78
Debt to Market Cap<0.01
Net Debt to EBITDA2.10
Interest Coverage Ratio-758.70
Taxes
In the past 12 months, Amplia Therapeutics has paid -4.78M in taxes.
Income Tax-4.78M
Effective Tax Rate0.38
Enterprise Valuation
Amplia Therapeutics EV to EBITDA ratio is -6.33, with an EV/FCF ratio of -9.45.
EV to Sales0.00
EV to EBITDA-6.33
EV to Free Cash Flow-9.45
EV to Operating Cash Flow-9.49
Balance Sheet
Amplia Therapeutics has AU$27.85M in cash and marketable securities with AU$341.11K in debt, giving a net cash position of AU$27.51M billion.
Cash & Marketable SecuritiesAU$27.85M
Total DebtAU$341.11K
Net CashAU$27.51M
Net Cash Per ShareAU$0.05
Tangible Book Value Per ShareAU$0.07
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Amplia Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast21.23%